Form 4: Citius Oncology Director Boosts Stake with New Share Grant

Citius Oncology Director Suren G. Dutia reported the acquisition of 300,000 restricted common shares and holds 275,000 stock options.

Summary

• Director Suren G. Dutia acquired 300,000 shares of Citius Oncology, Inc. common stock on September 19, 2025, through a restricted stock award.
• These restricted shares will vest in three substantially equal installments on the first, second, and third anniversaries of the grant date, contingent on continuous service to the company.
• Dutia also holds 125,000 stock options with an exercise price of $1.07, granted on December 12, 2024, which will vest 1/3 annually over three years, subject to continuous service.
• Additionally, Dutia holds 150,000 fully vested stock options with an exercise price of $2.15, expiring on July 5, 2033.
• Following these transactions, Dutia beneficially owns 300,000 direct common shares and 275,000 direct stock options.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock and grant of options by a director generally indicates alignment of interests with shareholders and confidence in the company's future, contributing to a moderately positive sentiment.

Positives

• Director Suren G. Dutia increased direct beneficial ownership of common stock by 300,000 shares, aligning management interests with shareholders.
• The grant of restricted stock and options serves as an incentive for the director's continued service and performance, promoting long-term commitment.

Risks

• The vesting of the 300,000 restricted shares and 125,000 stock options is contingent on the Reporting Person's continuous service to Citius Oncology, Inc. or a related entity as of the applicable vesting date.

Related Party Transactions

• Grant of 300,000 restricted common stock awards to Director Suren G. Dutia by Citius Oncology, Inc. on September 19, 2025.
• Grant of 125,000 stock options to Director Suren G. Dutia by Citius Oncology, Inc. on December 12, 2024.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through direct equity ownership and performance-based incentives.
• Employees: The vesting conditions tied to continuous service may reinforce retention and commitment among key personnel, including the reporting director.

Next Steps

• Vesting of 300,000 restricted shares in three equal annual installments starting September 19, 2026.
• Vesting of 125,000 stock options in three equal annual installments starting December 12, 2025.

Key Dates

Keywords

Citius Oncology, CTOR, Insider Trading, Form 4, Restricted Stock, Stock Options, Director Compensation, Beneficial Ownership